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Angiogenesis is considered a hallmark of multiple myeloma (MM) progression. In the present study, we evaluated the
morphological and functional features of endothelial cells (ECs) derived from bone marrow (BM) of patients affected by MM
(MMECs). We found that MMECs compared with normal BM ECs (BMECs) showed increased expression of syndecan-1. Silencing
of syndecan-1 expression by RNA interference technique decreased in vitro EC survival, proliferation and organization in
capillary-like structures. In vivo, in severe combined immunodeﬁcient mice, syndecan-1 silencing inhibited MMEC organization
into patent vessels. When overexpressed in human umbilical vein ECs and BMECs, syndecan-1 induced in vitro and in vivo
angiogenic effects. Flow-cytometric analysis of MMECs silenced for syndecan-1 expression indicated a decreased membrane
expression of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2). Immunoprecipitation and confocal analysis
showed colocalization of VEGFR-2 with syndecan-1. Absence of nuclear translocation of VEGFR-2 in syndecan-1-knockdown cells
together with the shift from perinuclear localization to recycling compartments suggest a role of syndecan-1 in modulation of
VEGFR-2 localization. This correlated with an in vitro decreased VEGF-induced invasion and motility. These results suggest that
syndecan-1 may contribute to the highly angiogenic phenotype of MMECs by promoting EC proliferation, survival and
modulating VEGF--VEGFR-2 signalling.
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INTRODUCTION
Multiple myeloma (MM) is a haematological malignancy
characterized by accumulation of clonal malignant plasma cells
predominantly within the bone marrow (BM)
1 and by increased
BM neovascularization.
2- -4 There is a direct correlation between
BM microvessel density and parameters of disease progression.
5
Moreover, increased BM vascularization in MM patients is
correlated with a poor prognosis.
6- -8Endothelial cells (ECs) derived
from MM patients signiﬁcantly differ from normal microvascular
ECs in terms of proliferation, phenotype, morphology and
capillarogenic activity.
9- -12 In patients affected by MM syndecan-1,
a heparan sulphate proteoglycan, is overexpressed by myeloma
cells in the BM and peripheral blood.
13,14 The high serum level of
shed syndecan-1 has been associated with an unfavourable
prognosis.
15,16 The presence of heparin sulphate chains allows
cell-to-cell and cell-to-extracellular matrix interactions. Moreover,
syndecan-1 is able to interact with several growth factors,
including pro-angiogenic factors such as vascular endothelial
growth factor (VEGF) and basic ﬁbroblastic growth factor.
17
Syndecan-1 seems to be able to modulate neovascularization
by increasing the local concentration of growth factors,
18 by
mediating their binding to speciﬁc receptors
19- -21 and/or by
interacting directly with the receptors.
22- -25 Expression of synde-
can is often altered in cancer,
26,27 and several studies suggest that
syndecan-1 expression promotes the growth of several malig-
nancies, including MM.
28- -31
The aim of the present study was to investigate whether
syndecan-1 was overexpressed on the surface of ECs derived from
the BM of MM patients (MMECs) as compared with normal BM ECs
(BMECs). Moreover, we investigated the functional implication of
syndecan-1 expression by MMECs in MM angiogenesis. Using an
RNA interference approach, to knockdown syndecan-1 expression,
we determinate the involvement of syndecan-1 in MMEC
proliferation, resistance to apoptosis, the ability to invade the
basal membrane, in vitro (2012) 26, 1082--1091. and in vivo
angiogenic properties, and responsiveness to VEGF stimulation.
MATERIALS AND METHODS
Patients
BM aspirates were collected from 10 MM patients at diagnosis. All patients
provided informed consent in accordance with local Institutional Review
Board requirements and the Declaration of Helsinki. Patient’s clinical
features are shown in Supplementary Table 1.
Cell lines
Primary microvascular EC lines from the BM of healthy donor (BMECs) or
MM patients (MMECs) were isolated. Brieﬂy, BM aspirates were centrifuged
on Ficoll (Biochrom AG, Berlin, Germany) gradient centrifugation and ECs
were isolated from mononuclear cells by using anti-CD31Ab coupled to
magnetic beads by magnetic cell sorting (MACS system, Miltenyi Biotec,
Auburn, CA, USA). Cells were recovered and transferred to six-well plates,
previously coated with Endothelial Cell Attachment Factor (Sigma, St Louis,
CA, USA) in 3-ml complete medium per well. Primary cultures of human
umbilical vein ECs (HUVECs) were isolated as described previously.
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completed with human epidermal growth factor, hydrocortisone and
bovine brain extract (all from Cambrex Bioscience, Walkersville, MD, USA),
with 10% fetal bovine serum (FBS).
Flow cytometry and immunoﬂuorescence
Cell phenotype was studied by ﬂow cytometry (FACSCalibur; Becton
Dickinson, San Jose, CA, USA) as described under Supplementary Materials
and methods. Immunoﬂuorescence studies for phenotype characterization
and confocal analysis of vascular endothelial growth factor receptor-2
(VEGFR-2) localization were performed as described under Supplementary
Materials and methods.
Syndecan-1 overexpression
The pOTB7 plasmid, containing the full coding region of human SDC1, was
purchased from Open Biosystems (Huntsville, AL, USA). The plasmid was
puriﬁed according to the Qiagen Plasmid mini kit protocol (Qiagen GmbH,
Hilden, Germany) and sent to Vector BioLabs (Philadelphia, PA, USA) for
AD-FRP-h synedecan-1 adenoviral vector construction. For virus infection,
BMECs or HUVECs were seeded at a density of 2 10
5cells/well in six-well
plates and infected with 0.5 10
6 IFU/p.f.u. (infectious unit/ml) of virus
preparation. After overnight absorption at 371C, the viral infection medium
was removed, cells were washed twice with phosphate-buffered saline and
fresh medium was added. Syndecan-1 overexpression was subsequently
analysed by ﬂow cytometry and quantitative reverse transcription-PCR
(qRT-PCR).
Cell proliferation and apoptosis assays
Cell proliferation was assessed by 5-bromo-20-deoxyuridine incorporation
and apoptosis by TUNEL assay as described under Supplementary
Materials and methods.
Apoptosis and cell-cycle arrays, and qRT-PCR
MMECs were compared with MMEC syndecan-1 small interfering RNA
(siRNA) and BMECs by PCR arrays and qRT-PCR (see Supplementary Table
2) as detailed under Supplementary Materials and methods.
Matrigel invasion and cell adhesion assays
Details on Matrigel invasion and cell adhesion assays are provided under
Supplementary Materials and methods.
Zymographic analysis
Gelatinolytic activity of matrix metalloproteinases (MMPs) was assessed
under non-reducing conditions using a modiﬁed sodium dodecyl sulphate-
PAGE. The supernatant, obtained after 24h of starvation, was mixed with
Laemmli buffer and loaded into an 8% polyacrylamide gel copolymerized
with 1mg/ml gelatin (Sigma). Electrophoresis and gel staining were
performed as described previously.
33 An aliquot of RPMI with 10% FBS was
used to determine the molecular weight of the gelatinase.
In vitro and in vivo angiogenesis assays
In vitro angiogenesis was studied by seeding cells on reduced growth
factor Matrigel-coated plates and in vivo angiogenesis by subcutaneous
injection of cells within Matrigel into severe combined immunodeﬁcient
(SCID) mice as described under Supplementary Materials and methods.
Immunoprecipitation
Cells were serum-starved for 24h and then lysed in cold DIM buffer (50mM
Pipes (pH 6.8), 100mM NaCl, 5mM MgCl2,3 0 0m M sucrose, 5mM EGTA) plus
1% Triton X-100 and a mixture of protease inhibitors (Sigma). Equal amount
(1mg) of proteins was immunoprecipitated using protein-A/G plus- -agarose
beads (Santa Cruz Biotechnology) pre-coated by an anti-syndecan-1 or a
VEGFR-2 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) (each at 2mg). Bound proteins were washed several times in DIM buffer
and resuspended in boiling Laemmli buffer. Resuspended proteins were then
subject to electrophoresis on Any kD sodium dodecyl sulphate-polyacryla-
mide gel (Bio-Rad Laboratories, Hercules, CA, USA), transferred to nitrocellu-
lose and probed with the appropriate antibody, followed by a horseradish
peroxidase-conjugated secondary antibody (Sigma) and an enhanced
chemiluminescent substrate (Thermo Scientiﬁc, Waltham, MA, USA).
EC migration assays
Details on EC migration assays are provided under Supplementary
Materials and methods.
RESULTS
Isolation and characterization of MMECs
MMECs and BMECs were isolated, respectively, from BM aspirates
of 10 different MM patients at diagnosis and four different healthy
donors. Flow-cytometric analysis showed that all the cell lines
isolated were endothelial; more than 95% cells expressed UEA-1,
VWF and CD144 (VE-cadherin) but not monocyte--macrophage
(CD14), leukocyte (CD45), plasma cell (CD38) markers and
mesenchymal cell markers (vimentin) (Figures 1a and b). The
MMECs phenotype was analysed in comparison with BMECs
(Supplementary Table 3). Both cell types expressed the same
levels of CD44, CD90, CD29, CD105, CD144 (VE-cadherin), CD146,
VEGFR-1 and VEGFR-3 and showed absence of CD154, CD34 and
CD133 expression. MMECs showed greater expression of CD40,
UEA-1, VEGFR-2 and, in particular, CD138 (syndecan-1) than BMECs
(Supplementary Table 3). The higher expression of syndecan-1 by
MMECs was not only at the protein level but also at the mRNA
level, as conﬁrmed by qRT-PCR (Figures 1c and d). At variance
between MMECs and BMECs, HUVECs did not express syndecan-1
protein and mRNA. For this reason HUVECs were used as control
for studies aimed to investigate the function of syndecan-1.
Syndecan-1 expression promotes proliferation and protects
against apoptosis
To analyse the role of syndecan-1 expression on MMECs, we used
an RNA interference approach. A pool of syndecan-1 siRNAs and,
as control, an scr-siRNA was transiently transfected into MMECs to
knock down syndecan-1 expression. Syndecan-1 siRNA, but not
scr-siRNA, transfection effectively inhibited syndecan-1 mRNA and
protein expression in MMECs (see Supplementary Figure 1 and
Supplementary Materials and methods). Then, to study the effect
of syndecan-1 knockdown on EC apoptosis and proliferation, we
compared the growth and apoptosis resistance of MMECs using
an MMEC syndecan-1 siRNA and, as control, an MMEC scr-siRNA.
An additional control included HUVECs. As shown in Figure 2a,
after 48h of culture with decreasing serum levels, MMECs
proliferated signiﬁcantly more than HUVECs. Transfection with
syndecan-1 siRNA, but not scr-siRNA, reduced this increase to
levels comparable to that of HUVECs. As internal control, cells
were grown in culture media (EBM 10% FBS) (Figure 2a). More-
over, to evaluate the effect of syndecan-1 expression on apoptosis
resistance, HUVECs, MMECs, MMEC syndecan-1 siRNA and, as
control, MMEC scr-siRNA, were grown for 24h in the absence of
serum (Figure 2b). As shown in Figure 2b, MMECs showed less
sensitivity to apoptosis, induced by serum deprivation, compared
with HUVECs. Knockdown of syndecan-1 expression (MMEC
syndecan-1 siRNA) determinated an increase in sensitivity to
apoptosis, even in the presence of serum. These results suggest
that expression of syndecan-1 on MMECs has a role in cell
proliferation and resistance to apoptosis. These effects seemed to
be independent from a reduced cell adhesion of syndecan-1-
knockdown cells, as both MMECs and MMEC syndecan-1 siRNA
showed the same ability to adhere to gelatin-coated plates on
which proliferation and apoptosis assays were performed (data
not shown).
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and apoptosis induction by syndecan-1 silencing, we investigated,
by PCR arrays, human cell-cycle and apoptosis pathways. The
results showed changes in genes involved in G2/M transition and
the M phase. GTP-binding RAS-like-3 was highly expressed by
syndecan-1-knockdown cells as compared with MMECs, whereas,
the levels of baculoviral inhibitor of apoptosis repeat containing-5
(BIRC5), cyclin-B1 (CCNB1), CDC28 protein kinase-regulatory
subunit-1B (CKS1B), CDC28 protein kinase-regulatory subunit-2
(CKS2), cyclin-B2 (CCNB2), cyclin-dependent kinase-1 (CDK1), cell
division cycle-20 homologue (CDC20) and antigen identiﬁed by
monoclonal antibody Ki-67 (MKi67) were decreased. These genes
were veriﬁed by qRT-PCR and were all signiﬁcantly changed as
compared with MMECs (Figure 3a). These results indicated an
arrest of syndecan-1-knockdown cells in G2/M transition and in the
M phase. The apoptosis array revealed that syndecan-1-knock-
down cells expressed elevated level of pro-apoptotic genes such
as BCL2-associated X protein (BAX) and tumor necrosis factor
receptor superfamily member-21 (TNFRSF21), whereas anti-
apoptotic genes, such as BCL2-like-10 (BCL2L10), baculoviral
inhibitor of apoptosis repeat containing-3 (BIRC3) and nucleolar
protein-3 (NOL3) were downregulated. qRT-PCR conﬁrmed
signiﬁcant variation of BAX, TNFRSF21, BCL2L10, BIRC3 and
NOL3 expression (Figure 3b). Interestingly, syndecan-1-knock-
down cells had low expression of BIRC3, whose encoded protein
inhibits apoptosis induced by serum deprivation. This suggests
that low membrane expression of syndecan-1 sensitizes the cells
to apoptosis induced by serum deprivation. The proﬁle of gene
analysis of BMECs, when compared with that of MMECs, showed a
signiﬁcant reduction of genes involved in M phase and a decrease
of anti-apoptotic genes and increase of pro-apoptotic genes
(Figures 3a and b).
Syndecan-1 expression promotes Matrigel invasion
We analysed MMEC basal membrane invasiveness and its
dependence on syndecan-1 expression. Thus, we compared
HUVECs, MMECs, MMEC syndecan-1 siRNA and, as control, the
MMEC scr-siRNA for ability to invade Matrigel in vitro. The results
showed that MMECs, as compared with HUVECs, showed
enhanced ability to invade Matrigel, whereas the MMEC synde-
can-1 siRNA, but not the MMEC scr-siRNA, showed a statistically
signiﬁcant decrease of this ability (Figure 4a). To evaluate whether
syndecan-1 expression correlated with MMP secretion, we tested
the gelatinolytic ability of HUVECs, MMECs, MMEC scr-siRNA and
MMEC syndecan-1 siRNA supernatants. MMECs, MMEC scr-siRNA
and HUVECs secrete activated MMP-2 (72-kDa form) and MMP-9
(83-kDa form). The MMEC values were, on average, 3 and 4 times
higher for MMP-2 and MMP-9, respectively, as demonstrated
previously
11 and there were no differences between MMECs and
MMEC scr-siRNA (data not shown). We detected a decrease in
both the 72 and 83-kDa bands of about 1.5 and 3 times,
respectively, in the MMEC syndecan-1 siRNA supernatant as
compared with the MMEC supernatant (Figure 4b). The presence
Figure 1. Characterization of HUVECs, BMECs and MMECs assessed by ﬂow-cytometric, immunoﬂuorescence and qRT-PCR analysis.
(a) Representative ﬂow-cytometric analysis showing isolated MMECs expressing CD31 and ulex europaeus agglutinin-1 (UEA-1) but not CD14
and CD38. The ﬂow-cytometric histograms are representative of six independent experiments with similar results. The dark lines represent the
MMECs and the dotted lines represent the corresponding isotype control antibody. (b) Representative confocal micrographs of vWF, vimentin
and VE-cadherin expression in BMECs and MMECs detected by immunoﬂuorescence. Original magniﬁcation:  400. (c, d) Comparison of
syndecan-1 mRNA expression by HUVECs, BMECs and MMECs using qRT-PCR (c) and ﬂow cytometry (d). (c) The normalized expression of the
genes with respect to ACTB was computed for all samples. Values are expressed as fold change with respect to HUVECs and are the mean±s.d.
of six independent experiments performed in triplicate. Student’s t-test was performed (*Po0.001 MMECs versus HUVECs;
wPo0.05 MMECs
versus BMECs). (d) Representative ﬂow-cytometric analysis showing syndeacan-1 expression in HUVECs (dotted line), BMECs (thin line) and
MMECs (dark line). The ﬂow-cytometric histograms are representative of six independent experiments with similar results.
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MMP-9 in MMEC syndecan-1 siRNA suggests a possible role of
syndecan-1 in the regulation of MMP secretion and in vitro MMEC
invasion ability. Syndecan-1 can promote cell adhesion and
invasion into the BM extracellular matrix.
34 In this contest we
analysed MMECs and MMEC syndecan-1 siRNA ability to adhere to
Matrigel. After 2h of incubation the MMEC syndecan-1 siRNA
showed decreased adhesion of about 40% compared with MMECs
(Figure 4c).
Syndecan-1 expression promotes in vitro and in vivo angiogenesis
When plated on growth factor-reduced Matrigel in the absence of
angiogenic stimulation, MMECs (Figure 5a, top right) formed an
extensive network of ring-like structures, whereas BMECs
(Figure 5a, top left, and Figure 5b) and HUVECs (Figure 5b)
showed a less organized vascular network. To evaluate whether
this enhancement was correlated with syndecan-1 expression, we
compared the ability of HUVECs, BMECs, MMECs, MMEC syndecan-
1 siRNA and, as control, MMEC scr-siRNA to form in vitro capillary-
like structures (Figures 5a and b). Syndecan-1 knockdown
signiﬁcantly inhibited the formation of vessel-like structures both
at 5 and at 24h (Figure 5a, bottom left, and Figure 5b). By contrast,
transfection with a control siRNA, MMEC scr-siRNA, did not affect
the endothelial organization (Figure 5a, bottom right, and
Figure 5b). Moreover, we evaluate the involvement of syndecan-
1 expression in the in vivo angiogenesis. For in vivo experiments
MMECs were transfected with syndecan-1 short-hairpin RNAs
(shRNAs) (MMEC syndecan-1 shRNA) to obtain a more stable
reduction of syndecan-1 expression and, as control, with an
scr-shRNA (MMEC scr-shRNA) (see Supplementary Figure 1 and
Supplementary Materials and methods). HUVECs, BMECs, MMECs,
MMEC syndecan-1 shRNA and, as control MMEC scr-shRNA were
injected subcutaneously within Matrigel in SCID mice. Seven days
after injection MMECs and to a less extent BMECs, but not HUVECs,
were able to organize in vessels connected with the murine
vasculature as shown by the presence of erythrocytes in the
lumen (Figure 5c, top right and left, and Figure 5e). Reduction of
syndecan-1 expression (MMEC syndecan-1 shRNA) was associated
with a signiﬁcant reduction of this ability (Figure 4c, bottom left,
and Figure 5e). By contrast, transfection with an shRNA control,
MMEC scr-shRNA, did not affect the ability of MMECs to form a
vascular structure in vivo (Figure 5c, bottom right, and Figure 5e).
The human nature of implanted MMECs was assessed by
immunoﬂuorescence staining for human CD31 and human
leukocyte antigen class-I (Figure 5d, left and right). Similar results
were obtained for BMECs (data not shown). Thus, inhibition of
syndecan-1 expression on MMECs was associated with a
signiﬁcant reduction of angiogenesis in vitro and in vivo, under-
lying the role of this protein in the MMEC angiogenic properties.
Figure 3. Cell-cycle and apoptosis-related genes are modulated
in syndecan-1-knockdown cells. Expression proﬁle of genes
involved in proliferation (a) and apoptosis (b) of MMEC syndecan-1
siRNA as compared with MMECs and BMECs by qRT-PCR. The
normalized expression of the genes with respect to gylceraldehyde-
3-phosphate dehydrogenase (GAPDH) was computed for all
samples. Values are expressed as fold change with respect to MMECs
and are the mean±s.d. of three independent experiments
performed in triplicate. Student’s t-test was performed (*Po0.05
MMECs syndecan-1 siRNA versus MMECs;
wPo0.05 BMECs versus
MMECs).
Figure 2. Syndecan-1 expression is associated with apoptosis
resistance and enhanced cell proliferation. (a) Cell proliferation after
48h of incubation in decreasing serum concentrations: RPMI 10%
FBS (black bars), 5% FBS (grey bars) and 2% FBS (light grey bars),
and, as control, culture media (complete EBM 10% FBS, white bar).
Data are expressed as the mean±s.d. of four experiments
performed in triplicate. Analysis of variance with Dunnett multiple
comparison test was performed (*Po0.01 MMECs versus HUVECs;
wPo0.05 MMEC syndecan-1 siRNA versus MMECs). (b) Apoptosis
after 24h of incubation in the presence (black bars) and absence of
serum (grey bars), and, as control, in culture media (complete EBM
10% FBS, white bars). Data are expressed as the mean±s.d. of four
experiments performed in triplicate. Analysis of variance with
Dunnett multiple comparison test was performed (*Po0.001 MMECs
versus HUVECs;
wPo0.001 MMEC syndecan-1 siRNA versus MMECs).
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in vitro and in vivo
To conﬁrm the role of syndecan-1 in the enhanced in vitro and
in vivo angiogenic properties of MMECs, we overexpressed
syndecan-1 in HUVECs (AD-FRP h-syndecan-1 HUVECs) and BMECs
(AD-FRP h-syndecan-1 BMECs) with an adenovirus coding the full
sequence of human syndecan-1 and, as control, with an empty
adenovirus (AD-FRP HUVECs, AD-FRP BMECs). qRT-PCR and ﬂow-
cytometric analysis showed that AD-FRP h-syndecan-1 HUVECs
and BMECs overexpressed syndecan-1 mRNA and protein (Figures
6a and b). We compared the ability of uninfected HUVECs and
BMECs with AD-FRP h-syndecan-1 HUVECs and AD-FRP
h-syndecan-1 BMECs to form capillary-like structures in vitro in
the absence of angiogenic stimulus. After 5h the extent of
capillary-like structure on Matrigel was signiﬁcantly enhanced in
AD-RFP h-syndecan-1 HUVECs and AD-FRP h-syndecan-1 BMECs as
compared, respectively, with uninfected HUVECs and BMECs
(Figures 6c and d). We did not measure any statistical difference
between uninfected and control cells (data not shown). Then, we
evaluated the effect of subcutaneous injection in SCID mice of
HUVECs and BMECs overexpressing syndecan-1 within Matrigel.
After 7 days, massive angiogenesis was observed with aneurysm-
like structures in mice injected subcutaneously with AD-FRP
h-syndecan-1 HUVECs or AD-FRP h-syndecan-1 BMECs (Figure 6e,
right), but not with AD-FRP HUVECs or AD-FRP BMECs (Figure 6e,
left). The human origin of vessels formed by AD-FRP h-syndecan-1
HUVECs was veriﬁed by immunoﬂuorescence for human CD31
and human leukocyte antigen class-I (Figure 6f, left and right).
Similar results were obtained for AD-FRP h-syndecan-1 BMECs
(data not shown). The areas of capillaries and aneurysm-like
structures penetrating the Matrigel plugs were quantiﬁed in
relation to the total Matrigel area. The percentage of vessel-like
areas was signiﬁcantly increased in AD-FRP h-syndecan-1 HUVECs
or AD-FRP h-syndecan-1 BMECs as compared with AD-FRP HUVECs
or AD-FRP BMECs (Figure 6g) We did not measure any statistical
difference between uninfected and control cells (data not shown).
Syndecan-1 expression mediates VEGF--VEGFR-2 signalling
Analyzing the phenotype of MMECs versus syndecan-1-knock-
down MMECs we found that syndecan-1 silencing determinated a
decrease in the expression of VEGFR-2 (Figure 7Aa). Conversely,
induced syndecan-1 overexpression on BMECs and HUVECs
increased VEGFR-2 protein expression (Figure 7Ab and c). Thus,
we analysed the possibility that sydecan-1 could physically
interact with VEGFR-2 and form an active complex at the
membrane of MMECs. We observed that an anti-syndecan-1
antibody was able to precipitate two proteins of about 200 and
230kDa, respectively, corresponding to two of the three isoforms
of VEGFR-2, as shown by anti-VEGFR-2 immunoblots (Figure 7B,
top). The speciﬁcity of this interaction was demonstrated by co-
immunoprecipitation experiments using an antibody against
VEGFR-2 (Figure 7B, bottom). Colocalization between VEGFR-2
and syndecan-1 in MMECs was also observed also by confocal
microscopy (Figure 7C). These results indicated that syndecan-1
was associated to VEGFR-2. We then hypothesized that VEGFR-2
localization might be regulated by syndecan-1 expression. As seen
by ﬂow-cytometric analysis (Figure 7Aa) and confocal microscopy
(Figure 7C), syndecan-1 silencing decreased the surface expression
of VEGFR-2. As shown by immunoﬂuorescence in permeabilized
cells, the intracellular distribution of VEFGR-2 in MMECs was
predominantly peri-nuclear, whereas in syndecan-1-knockdown
cells it was cytoplasmic (Figure 7D) and colocalized with Ras-
related in brain-11 (Rab11), a marker of the long-loop recycling
pathway (Figure 7E). Similar results were observed with the Early
Endosome Antigen-1 (EEA1) (data not shown). By contrast, in
MMECs VEGFR-2, which was mainly perinuclear (Figure 7D),
showed only minimal colocalization with the recycling markers
(Figure 7E). No colocalization of VEGFR-2 was seen with either the
Golgi Membrane protein-130 (GM130) or the marker of the Trans-
Golgi Network-38 (TGN38) (data not shown). Moreover, nuclear
translocation of VEGFR-2 after VEGF stimulation was almost
completely abrogated in syndecan-1-knockdown cells
(Figure 7F). A reduced synthesis of VEGFR-2 was also suggested
by its reduced transcription as shown in Figure 7G.
Thus, we analysed the effect of syndecan-1 silencing in VEGF-
induced motility. In basal condition, all cells analysed were found
to remain steady for the whole period of observation, never
exceeding an average speed of 11--13ı `m/h. Stimulation with VEGF
Figure 4. Syndecan-1 expression is associated with invasion
properties of MMECs. (a) Invasion of HUVECs, MMECs and MMEC
syndecan-1 siRNA and, as control, MMEC scr-siRNA towards
Matrigel-coated ﬁlters was evaluated. Cells that migrated to the
underside of the ﬁlters were counted in ﬁve microscope ﬁelds in
each well at  100 magniﬁcation. Data are expressed as the
mean±s.d. of four experiments performed in duplicate. Analysis of
variance with Dunnett multiple comparison test was performed
(*Po0.001 MMECs versus HUVECs;
wPo0.001 MMEC syndecan-1
siRNA versus MMECs). (b) Representative zymographic analysis of
MMECs and MMEC syndecan-1 siRNA. The ﬁrst lane (FBS) shows the
control RPMI supplemented with 10% FBS. The clear bands
represented gelatinase activity. Four experiments were performed
with similar results. (c) Evaluation of MMECs and MMEC syndecan-1
siRNA attachment on growth factor-reduced Matrigel after 2h in
media used for invasion assay (not complete EBM with 10% FBS).
Data are expressed as ±s.d. of three different experiments each in
triplicate. Student’s t-test was performed (*Po0.001).
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and b). In particular, MMECs showed a major response to the VEGF
stimulus than HUVECs, as they reached a speed of approximately
26mm/h, whereas HUVEC motility was about 19mm/h. Knockdown
of syndecan-1 expression on MMECs abrogated VEGF-dependent
EC migration, reducing the speed average to basal levels (Figures
8a and b). The effects persisted for the whole period of
observation (Figure 8a). Moreover, we analysed the effect of
syndecan-1 knockdown on invasion in the presence of 25ng/ml
VEGF. After 48h, both HUVECs and MMECs showed an increased
ability to invade Matrigel in the presence of VEGF, as compared
with the basal condition (Figure 8c). Conversely, syndecan-1
knockdown abrogated the VEGF-induced invasiveness of MMECs
to levels comparable to that of HUVECs (Figure 6e).
DISCUSSION
In the present study, we found that ECs obtained from the BM of
patients with MM overexpressed syndecan-1 and we provide
evidence that its expression contributes to their proliferative,
apoptosis-resistant, pro-invasive and pro-angiogenic phenotype.
Previous studies suggested that overexpression of syndecan-1
by MM cells correlates with disease progression.
30,35- -38 We here
demonstrated that also MMECs overexpress this proteoglycan in
respect to ECs derived from normal BM. As the functional
signiﬁcance of syndecan-1 expression by MMECs has not been
investigated before, we examined its role in angiogenesis. It has
been suggested that syndecan-1-retaining heparin-binding factors
within the BM microenvironment may provide a support for the
growth and survival of tumor plasma cells.
34,39 Here we suggested
that syndecan-1 could be also involved in the modulation of the
growth and survival of ECs within the BM microenvironment. In
fact, knockdown of syndecan-1 expression by RNA interference
resulted in arrest of the cell in G2/M transition and M phase, and
enhanced the sensitivity of MMECs to apoptosis. Moreover, in the
present study we found that syndecan-1 expression correlated
with enhanced in vitro and in vivo angiogenic activity. Indeed,
downregulation of syndecan-1 was associated with a decreased
in vitro capillary like-structure and in vivo angiogenic network
Figure 5. Effect of syndecan-1 expression on in vitro and in vivo MMEC angiogenesis. (a) Representative micrographs of capillary-like structure
formation on Matrigel formed by BMECs (top left), MMECs (top right), MMEC syndecan-1 siRNA (bottom left) and MMEC scr-siRNA (bottom
right) after 24h of incubation. Original magniﬁcation,  100. (b) Morphometric evaluation of capillary-like structures formed onto Matrigel
after 5h (grey bars) and 24h (black bars). Data are expressed as the mean±s.d. of the length of capillary-like structures evaluated, in arbitrary
units by the computer analysis system, in six different experiments performed in triplicate. Analysis of variance with Newman--Keuls multi-
comparison test was performed (*Po0.001 MMECs and MMEC scr-siRNA versus HUVECs;
wPo0.001 MMECs and MMEC scr-siRNA versus BMECs;
zPo0.001 MMEC syndecan-1 siRNA versus MMECs;
yPo0.05 MMEC syndecan-1 siRNA versus BMECs). (c, d) HUVECs, BMECs, MMECs, MMEC
syndecan-1 shRNA and, as control, MMEC scr-shRNA within Matrigel were injected subcutaneously into SCID mice. Mice were killed after 7
days and Matrigel plugs were submitted for histological analysis. (c) Representative micrographs (haematoxylin/eosin staining) of Matrigel-
containing BMECs (top left), MMECs (top right), MMEC syndecan-1 shRNA (bottom left) and MMEC scr-shRNA (bottom right). BMECs, MMEC
syndecan-1 shRNA and MMEC scr-shRNA showed formation of vessels containing blood erythrocytes. Original magniﬁcation,  200. (d)
Representative confocal micrograph showing expression of human CD31 (left) and human leukocyte antigen class-I (right) on neo formed
vessels in Matrigel by MMECs. Original magniﬁcation,  400. (e) Quantitative evaluation of angiogenesis in a section of Matrigel plugs stained
by haematoxylin/eosin staining. Angiogenesis was evaluated as the percentage of vessels area in ﬁve different ﬁelds at  100 magniﬁcation.
Only vascular structures containing red blood cells were counted as vessels. The data are the mean±s.d. of ﬁve individual experiments.
Analysis of variance with Newman--Keuls multi-comparison test was performed (*Po0.001 MMECs and MMEC scr-shRNA versus HUVECs;
wPo0.001 MMECs and MMEC scr-siRNA versus BMECs;
zPo0.001 MMEC syndecan-1 siRNA versus MMECs).
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stimulated MMEC organization into in vitro capillary-like structures
and in vivo vessel formation. These results are in line with data
suggesting a physiological role of syndecan-1 in the formation of
new vessels.
17,40 Moreover, after syndecan-1 knockdown we
observed a decreased production of active MMP-2 and MMP-9
Figure 6. Syndecan-1 overexpression enhanced in vitro HUVEC and BMEC angiogenic ability. (a) Syndecan-1 mRNA level was analysed by qRT-
PCR in AD-FRP h-syndecan-1 HUVECs or BMECs. The normalized expression of the SDC1 gene with respect to GAPDH was computed for all
samples. Uninfected HUVECs and BMECs were used as control (*Po0.05 AD-FRP h-syndecan-1 HUVECs versus uninfected HUVECs; *Po0.01
AD-FRP h-syndecan-1 BMECs versus uninfected BMECs). (b) Representative ﬂow-cytometric histogram of syndecan-1 overexpression on
HUVECs and BMECs. The thin line represents AD-FRP HUVECs or AD-FRP BMECs, infected with an empty adenovirus, and the dark line
represents the AD-FRP h-syndecan-1 HUVECs or AD-FRP h-syndecan-1 BMECs, overexpressing syndecan-1; the dotted line represents the
isotypic control. (c) Representative micrographs of capillary-like structure formation on Matrigel by uninfected HUVECs (top left), AD-FRP
h-syndecan-1 HUVECs (top right), uninfected BMECs (bottom left) and AD-FRP h-syndecan-1 BMECs (bottom right) after 5h. Original
magniﬁcation,  100. (d) Morphometric evaluation of capillary-like structures formed onto Matrigel. Data are expressed as the mean±s.d. of
the length of capillary-like structures detected in ﬁve different ﬁelds of four different experiments performed in triplicate. Original
magniﬁcation,  100. Analysis of variance with Newman--Keuls multi-comparison test was performed (*Po0.001 AD-FRP h-syndecan-1 versus
uninfected HUVECs;
wPo0.01 AD-FRP h-syndecan-1 versus uninfected BMECs). (e) Representative micrographs of Matrigel-containing AD-FRP
HUVECs (left), as control, and AD-FRP h-syndecan-1 HUVECs (right), and AD-FRP BMECs (left), as control, and AD-FRP h-syndecan-1 BMECs
(right) injected subcutaneously into SCID mice. Original magniﬁcation,  200. The inset shows formation of aneurism-like structure by AD-FRP
h-syndecan-1 BMECs. Original magniﬁcation,  100. (f) Representative confocal micrograph showing expression of human CD31 (bottom left)
and human leukocyte antigen class-I (bottom right) on neo formed vessels within Matrigel by AD-FRP h-yndecan-1 HUVECs. Original
magniﬁcation,  400. (g) Morphometric analysis of new formed vessels within Matrigel. Data are expressed as the mean±s.d. of the length of
capillary-like structures of ﬁve individual experiments. Only vascular structures containing red blood cells were counted as vessels. Original
magniﬁcation,  100. Analysis of variance with Newman--Keuls multi-comparison test was performed (*Po0.001 AD-FRP h-syndecan-1 versus
AD-FRP HUVECs; wPo0.001 AD-FRP h-syndecan-1 versus AD-FRP BMECs).
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invasion. These results suggest that syndecan-1 can promote
endothelial invasion into the extracellular matrix directly or
indirectly regulating MMPs. We also showed decreased adherence
of syndecan-1-knockdown MMECs to Matrigel. This result suggests
that syndecan-1, by mediating also cell-to-matrix interactions,
34
Figure 7. Syndecan-1 regulates VEGFR-2 expression. (A) Representative ﬂow-cytometric analysis showing VEGFR-2 expression by (a) MMECs
(thin line), MMEC syndecan-1 shRNA (dark line) and the corresponding isotype control antibody (dotted line); (b) BMECs (thin line), AD-FRP
h-syndecan-1 BMECs (dark line) and the corresponding isotype control antibody (dotted line); and (c) HUVECs (thin line), AD-FRP h-syndecan-1
HUVECs (dark line) and the corresponding isotype control antibody (dotted lines). The ﬂow-cytometric histograms are representative of three
independent experiments with similar results. (B) Syndecan-1 immunoprecipitated with VEGFR-2. The immune complexes were formed by
pre-incubation with anti-syndecan-1 and revealed with an antibody to VEGFR-2 (top), or by pre-incubation with anti-VEGFR-2 and revealed
with an antibody to syndecan-1 (bottom). The data are from an individual experiment and are representative of two different lines of MMECs.
(C) Representative confocal micrographs showing colocalization of VEGFR-2 and syndecan-1 on cellular membrane under the non-
permeabilized condition (original magniﬁcation,  630). (D) Representative confocal micrographs showing intracellular expression of VEGFR-2
in permeabilized cells (original magniﬁcation,  630). (E) Representative confocal micrographs showing colocalization between VEGFR-2 and
Rab11 in permeabilized cells (original magniﬁcation,  630). (F) Representative confocal micrographs showing VEGFR-2 localization 30min
after stimulation with VEGF (25ng/ml) (original magniﬁcation,  630). (G) Comparison of VEGFR-2 mRNA expression between MMECs and
MMEC syndecan-1 shRNA by qRT-PCR. The normalized expression of the genes with respect to GAPDH was computed for all samples. Values
are expressed as fold change with respect to MMECs and are the mean±s.d. of three independent experiments performed in triplicate.
Student’s t-test was performed (*Po0.001 MMEC syndecan-1 shRNA versus MMECs).
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On the other hand, we demonstrated that acquisition by HUVECs
and overexpression in BMECs of syndecan-1 induced a phenotype
similar to that of MMECs. In fact, HUVECs and BMECs over-
expressing syndecan-1 showed an enhanced ability to form
capillary-like structure in vitro. Moreover, HUVECs and BMECs
overexpressing syndecan-1 acquired a highly angiogenic pheno-
type when injected in Matrigel in SCID mice. These data suggest
that syndecan-1 expression may inﬂuence the angiogenic
behaviour of ECs contributing to the acquisition of an activated
phenotype. This phenotype may depend not only on an enhanced
cell-to-cell interaction and production of MMPs, but also on an
enhanced response to pro-angiogenic factors. Indeed, comparing
the MMEC phenotype versus that of syndecan-1-knockdown
MMECs, we observed a decrease of VEGFR-2 surface expression.
Immunoprecipitation studies demonstrated a physical interaction
between syndecan-1 and VEGFR-2. This observation is consistent
with the ability of syndecan-1 to interact with this growth factor
receptor.
22,23 Moreover, we found that syndecan-1 silencing
correlated with a reduced ability of MMECs to respond to VEGF.
This may depend on a modulatory role of syndecan-1 on VEGFR-2
expression. Indeed, after syndecan-1 silencing reduced VEGFR-2
surface expression and its preeminent localization within the
cytoplasm in association with the endosomal recycling compart-
ments was observed. These results suggest that the syndecan-1
expression prevents the intracellular recycling of VEGFR-2 and is
relevant for maintaining the receptor within the plasma mem-
brane, thus allowing interaction with its ligand. Moreover, nuclear
translocation of VEGFR-2 after interaction with VEGF,
41,42 which
has been suggested to regulate its synthesis,
43 was almost
completely absent in syndecan-1-knockdown cells. In agreement
with this hypothesis, we observed a reduced expression of
VEGFR-2 mRNA in syndecan-1-knockdown cells.
Previous studies demonstrated that syndecan-1 expression by
plasma cells and its soluble form have a prognostic value.
16,30
Therefore, syndecan-1 has been considered a potential therapeutic
target in MM. Several studies have successfully developed different
syndecan-1 inhibition strategies.
35,37,38,44,45 A phase-I clinical study
is ongoing using a cytotoxin-conjugated antibody against synde-
can-1 (BT062).
46 The present ﬁnding that also MMECs express high
levels of syndecan-1 with functional relevance in tumor angiogen-
esis extends the potential beneﬁcial effect of syndecan-1 targeting
against MM progression, acting both on the tumoral cell and the
BM microenvironment. However, it remains to be determined
whether syndecan-1 blockade might interfere with physiological
angiogenesis. Further studies are needed to investigate whether
syndecan-1 expression may deﬁne an angiogenic proﬁle and
correlate with cytogenetics and patient outcome.
In conclusion, the results of the present study provide a novel insight
into regulation of MM angiogenesis by syndecan-1 and suggest that
impairment of physiological function of syndecan-1 could be an
interesting therapeutic approach for treatment of this malignancy.
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Figure 8. Syndecan-1 expression modulates VEGF-induced motility
and migration. (a) Motility of HUVECs (m), MMECs (’) and MMEC
syndecan-1 siRNA (E) in the presence (thin line) or absence (dotted
line) of a VEGF stimulus (25ng/ml) was monitored by time-lapse
analysis for a period of 14h and measured in mm/h as described
under Materials and methods. (b) Speed average after 10h of
incubation in the presence (black bar) and absence (white bar) of a
VEGF stimulus (25ng/ml). The results are the mean±s.d. of four
individual experiments evaluating at least 30 cells for each
experimental condition. Analysis of variance with Dunnett multiple
comparison test was performed (*Po0.001 MMECs versus HUVECs;
wPo0.001 MMEC syndecan-1 siRNA versus MMECs;
zPo0.05 VEGF
stimulus (black bar) versus without VEGF stimulus (white bar)). (c)
Invasion of HUVECs, MMECs and MMEC syndecan-1 siRNA towards
Matrigel-coated ﬁlters was evaluated. VEGF (25ng/ml) was added
(black bar) or not added (white bar) to the lower chamber. Cells that
migrated to the underside of the ﬁlters were counted in ﬁve
microscope ﬁelds in each well. Original magniﬁcations,  100. Data
are expressed as the mean±s.d. of four independent experiments
performed in duplicate. Analysis of variance with Dunnett multiple
comparison test was performed (*Po0.001 MMECs versus HUVECs;
wPo0.001 MMEC syndecan-1 siRNA versus MMECs;
zPo0.001 VEGF
(black bar) versus without VEGF (white bar)).
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